Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20230314057712N1
IRCT20230314057712N1
Recruiting
Phase 4

Comparison of efficacy and safety of empagliflozin with placebo in patients with idiopathic edema

Ahvaz University of Medical Sciences0 sites70 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsIdiopathic edema.Edema, unspecifiedR60.9

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Idiopathic edema.
Sponsor
Ahvaz University of Medical Sciences
Enrollment
70
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients over 18 years of age who refer due to generalized edema
  • •The patient does not take drugs that cause edema
  • •In the diagnostic investigations, there are no disorders, including kidney, heart, liver, thyroid, etc. There should be no justification and cause of generalized edema for the patient

Exclusion Criteria

  • •Patients who do not want to cooperate and participate in the research
  • •Patients with diseases such as advanced renal failure, liver failure, chronic or recurrent UTI
  • •Patients with immune deficiency or diabetes
  • •Patients who use drugs that interfere with the intervention process

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not Yet Recruiting
Phase 3
Comparison of therapeutic effect of Empagliflozin (Gloripa) and Sitagliptin (Ziptin) on type 2 Diabetic patients
IRCT20200810048355N1Vice Chancellor for Research, Islamic Aazad University, Najafabad branch128
Recruiting
Phase 3
Evaluation of the effectiveness of Empagliflozin on metabolic factors and liver function tests
IRCT20191209045671N3Semnan University of Medical Sciences60
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02
IRCT20220902055858N1Shahre-kord University of Medical Sciences90
Not Yet Recruiting
Phase 4
Efficacy and Safety of empagliflozin in patients with hepatic ascites: a randomized controlled trialDigestive System
PACTR202402866059449one60
Not Yet Recruiting
Phase 3
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patients
CTRI/2024/02/063292SRM Insitute of Science and Technology